Andrew Obenshain Becomes CEO of Inventiva
Inventiva, a clinical-stage biopharmaceutical company well-regarded for its innovative approaches in treating metabolic dysfunction-associated steatohepatitis (MASH), recently announced a notable leadership change. Andrew Obenshain has been appointed as the new Chief Executive Officer (CEO) of the company, succeeding Frédéric Cren, who co-founded Inventiva and has been at the helm since its establishment.
A Strategic Transition for Growth
This change in leadership signifies a pivotal evolution in Inventiva's journey towards increased growth and development. With a firm commitment to expanding the company’s global impact, Mr. Obenshain is poised to enhance the strategies for potential commercialization of MASH treatments in pivotal markets, including the United States.
Insight from the Board
Mark Pruzanski, MD, Chairman of the Board, expressed his enthusiasm for the change, highlighting that the upcoming Phase 3 data and the pre-commercialization efforts are vital. He believes that Andrew's extensive global experience in drug approvals and keen patient-centric leadership will solidify Inventiva's standing in the competitive MASH field. This anticipated success could pave the way for bringing lanifibranor, a novel treatment, to patients around the world.
Reflections from Frédéric Cren
Frédéric Cren shared heartfelt reflections on his tenure, stating that founding Inventiva and shepherding it through significant milestones was profoundly rewarding. He emphasized the transformation from a concept into a leading biopharma entity, recognizing the remarkable contributions of team members throughout this journey. Cren’s commitment to supporting the transition reflects a dedication to maintaining Inventiva’s strategic momentum.
Obenshain’s Vision for the Future
Andrew Obenshain acknowledged the foundational work laid by Frédéric Cren and expressed his enthusiasm for the company’s future. His focus will be on preparing the organization for the challenges ahead, ensuring that Inventiva is equipped to deliver innovative solutions to patients globally. With a strong commitment to scientific excellence and patient care, Obenshain aims to redefine standard care practices in treating MASH.
Background on Andrew Obenshain
Before joining Inventiva, Andrew Obenshain served as the CEO of bluebird bio, now known as Genetix Biotherapeutics. He spearheaded initiatives that led to the company’s development into a prominent gene therapy firm by successfully navigating multiple regulatory approvals in vital global markets. Obenshain boasts over 20 years of experience in drug development and commercialization and has held significant roles in organizations like Shire and Genzyme/Sanofi, emphasizing his expertise in rare diseases and specialty therapeutics.
Understanding MASH and Inventiva's Role
Inventiva is recognized for its crucial role in developing treatments for MASH, which is increasingly being recognized as a widespread condition that significantly affects liver health. The company's flagship therapeutic, lanifibranor, is currently undergoing trials in the pivotal NATiV3 Phase 3 clinical study, highlighting its commitment to advancing patient care through innovative therapies.
The Path Ahead for Inventiva
As Inventiva transitions under Obenshain’s leadership, the focus will be on not just achieving regulatory approvals, but also on creating an infrastructure ready for successful commercial operations once the product enters the market. This strategic growth phase aligns with the company’s goals of building a robust global presence.
Frequently Asked Questions
Who is the new CEO of Inventiva?
Andrew Obenshain has been appointed as the new CEO of Inventiva, succeeding Frédéric Cren.
What is Inventiva's primary focus?
Inventiva is focused on developing oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
How long did Frédéric Cren serve as CEO?
Frédéric Cren served as the CEO of Inventiva from its founding in 2012 until 2025.
What is the significance of lanifibranor?
Lanifibranor is Inventiva's primary candidate in development for treating MASH and is undergoing pivotal clinical trials.
What are Inventiva's goals moving forward?
The company aims to prepare for potential commercialization of its therapies while expanding its global market presence.
